It seems to me that due to Virax having so little going for it in its own right, supporters of the stock are seeking to justify their holding by recourse to entirely general, industry considerations.
Biotechs succeed or fail on their own merits/according to their own trial results; not the merits of the generic type of technology they are pursuing.
